Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience.

IF 1.2 Q4 ONCOLOGY Hepatic Oncology Pub Date : 2021-06-04 eCollection Date: 2021-09-01 DOI:10.2217/hep-2020-0035

Gerardo Tovar-Felice, Andrés García-Gámez, Virgilio Benito-Santamaría, David Balaguer-Paniagua, Jordi Villalba-Auñón, Jaume Sampere-Moragues

{"title":"Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience.","authors":"Gerardo Tovar-Felice, Andrés García-Gámez, Virgilio Benito-Santamaría, David Balaguer-Paniagua, Jordi Villalba-Auñón, Jaume Sampere-Moragues","doi":"10.2217/hep-2020-0035","DOIUrl":null,"url":null,"abstract":"Background: Transarterial chemoembolization (TACE) is indicated for unresectable hepatocellular carcinoma.Methods: This was a retrospective study of 50 hepatocellular carcinoma patients treated with TACE using doxorubicin-loaded LifePearl™ to investigate the safety and efficacy of TACE.Results: There was no 30-day mortality, and limited adverse events were reported. At best tumor response, complete response and disease control were 58% and 94%, respectively, with a median of 4.5 months of follow-up. Median overall survival was 33.8 months. Patients with Barcelona Clinic Liver Cancer stage 0 and stage A at best tumor response showed a higher complete response rate (83%) than patients with Barcelona Clinic Liver Cancer stage B (complete response: 50%; p = 0.0414).Conclusion: Doxorubicin-loaded LifePearl™ TACE might be an effective treatment, with a good safety profile, for patients with early/intermediate-stage hepatocellular carcinoma. Further prospective data, especially with a small cohort of selected patients, are required to confirm these results.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"8 3","pages":"HEP38"},"PeriodicalIF":1.2000,"publicationDate":"2021-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/44/5b/hep-08-38.PMC8369521.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/hep-2020-0035","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Background: Transarterial chemoembolization (TACE) is indicated for unresectable hepatocellular carcinoma.

Methods: This was a retrospective study of 50 hepatocellular carcinoma patients treated with TACE using doxorubicin-loaded LifePearl™ to investigate the safety and efficacy of TACE.

Results: There was no 30-day mortality, and limited adverse events were reported. At best tumor response, complete response and disease control were 58% and 94%, respectively, with a median of 4.5 months of follow-up. Median overall survival was 33.8 months. Patients with Barcelona Clinic Liver Cancer stage 0 and stage A at best tumor response showed a higher complete response rate (83%) than patients with Barcelona Clinic Liver Cancer stage B (complete response: 50%; p = 0.0414).

Conclusion: Doxorubicin-loaded LifePearl™ TACE might be an effective treatment, with a good safety profile, for patients with early/intermediate-stage hepatocellular carcinoma. Further prospective data, especially with a small cohort of selected patients, are required to confirm these results.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

阿霉素洗脱聚乙二醇微球治疗不可切除的肝细胞癌:单中心经验。

背景:经动脉化疗栓塞(TACE)适用于不可切除的肝细胞癌。方法:回顾性研究50例接受TACE治疗的肝癌患者，采用负载多柔比星的LifePearl™，探讨TACE的安全性和有效性。结果:无30天死亡率，不良事件有限。最佳肿瘤缓解、完全缓解和疾病控制分别为58%和94%，中位随访时间为4.5个月。中位总生存期为33.8个月。在最佳肿瘤反应时，巴塞罗那临床肝癌0期和A期患者的完全缓解率(83%)高于巴塞罗那临床肝癌B期患者(完全缓解:50%;P = 0.0414)。结论:负载多柔比星的LifePearl™TACE可能是早期/中期肝细胞癌患者的有效治疗方法，具有良好的安全性。需要进一步的前瞻性数据，特别是选择的小队列患者，来证实这些结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.